TEVA seeking to acquire AGN’s generic-drug business (i.e. the former Watson/Actavis) for ~$45B, according to sources: http://www.wsj.com/articles/teva-in-advanced-talks-to-buy-allergans-generic-drug-unit-1437861351 If the above deal is consummated, TEVA would no longer pursue its hostile offer for MYL.